Antagonists of Hyaluronan Signaling for Treatment of Airway Inflammation and Hyperresponsiveness
Posted Jul 02 2012 8:00pm
Description of Invention: Airway inflammation and hyperresponsiveness are hallmarks of airway disease. Investigators at NIEHS identified a new class of compounds that can block hyaluronan signaling and inhibit airway hyperresponsiveness and inflammation. Airway diseases, such as asthma and chronic obstructive airway disease, affect tens of millions of patients worldwide, and are chronic diseases with limited options for treatment (bronchodilators and inhaled steroids are the two classes of drugs currently in common use). Therefore, a novel class of treatment agents could have significant public health and market impact.
Applications: Treatment of Airway Inflammation and Hyperresponsiveness.
Advantages: Potentially cost-effective treatment for widespread conditions.
Development Status: In vitro data available
Inventors: Stavros Garantziotis (NIEHS) John W Hollingsworth (Duke University Medical Center) Bryan P Toole (Medical University of South Carolina) Jian Liu (University of North Carolina - Chapel Hill)
Collaborative Research Opportunity: The NIEHS is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize the use of hyaluronan antagonists to treat chronic respiratory diseases. For collaboration opportunities, please contact Elizabeth M. Denholm, Ph.D. at email@example.com .
For Licensing Information Please Contact: Jaime Greene M.S. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: firstname.lastname@example.org Phone: 301-435-5559 Fax: 301-402-0220